Question Bank › Old money out, new money in

Old money out, new money in

Old money out, new money in: the company is redirecting its own capital away from what it has always done and into a spe

Calls Tested
475
Answered YES
24
Hit Rate
5.1%
rare by design

Fate Therapeutics, Inc. (FATE) — this company's answers

NO on the Q3 2016 call 2016-11-07 C
The model's full reasoning — Q3 2016 call → NOWe need answer YES or NO based on transcript. Need determine if management describes redirection of company's own capital/operating resources from historical activity to newer effort, with all three criteria. Transcript: Fate Therapeutics. Programs: ProTmune (hematopoietic cell transplant graft), FATE-NK100 (NK cell cancer immunotherapy), ToleraCyte (CD34+ cell therapy for autoimmune), iPSC-derived off-the-shelf NK/T cell platform. Need see if management says resources are being redirected from one to another. Historically? Company developing cellular immunotherapies, ProTmune lead clinical product. Now they have multiple programs. Are they shifting resources away from ProTmune to something else? No, they are intensifying clinical commitment to each program. They mention "intensified our clinical commitment to each of our programs." ProTmune still lead. They added blinding, expanded eligibility. FATE-NK100 IND filed. ToleraCyte pre-IND. iPSC platform. But no indication that incremental resources are flowing into one newer effort and away from historical activity. They are adding initiatives on top. Also no "something getting less." They mention "While this has initially delayed enrollment in Phase I stage" due to protocol amendment, but that's not resource reallocation. They are not reducing ProTmune investment. They say "substantial progress and intensified our clinical commitment to each of our programs." So answer NO. Need be careful: Could there be redirection from patient-specific cell therapy to off-the-shelf iPSC? They say "We have now initiated clinical translation of our first off-the-shelf product candidate..." But they are still advancing ProTmune and NK100. They describe iPSC as "disruptive approach" but not that they are shifting resources away from existing. They formed partnership with MSK. But no mention of reducing other programs. They are adding. So NO. Final answer: NO.

← Back to the full FATE analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe that THE COMPANY'S OWN CAPITAL AND OPERATING RESOURCES ARE NOW BEING POINTED SOMEWHERE DIFFERENT THAN THEY HISTORICALLY WENT — that is, is there a visible, already-executing redirection in which the company's incremental money, capacity, people, or attention is flowing INTO one identifiable newer effort and correspondingly AWAY FROM the activity that has historically consumed those resources — with management treating this reallocation as the thing that will define what the company becomes? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent redirection with all three of the following coming through as a present-tense reality: (1) THE DESTINATION IS IDENTIFIABLE AND ALREADY BEING FUNDED AT REAL SCALE. Management names or clearly identifies where the resources are going — a newer product line, technology, service, format, facility type, market, customer class, channel, business model, or capability — and describes real resources ALREADY committed to it and in motion now: money being spent, capacity being built or converted, people hired or reassigned, sites opened, inventory or supply purchased, programs staffed. The destination need not yet be large in the results, and management may be candid that it is early; what matters is that the funding is actually flowing today rather than being planned, budgeted for later, or contingent on financing, approvals, or decisions not yet obtained. (2) SOMETHING IS VISIBLY GETTING LESS. Management conveys, directly or plainly in substance, that the historical use of the company's resources is no longer where the incremental investment goes — for example capital spending shifted away from the legacy area; a mature line, market, or asset base being maintained, harvested, or deliberately not reinvested in; capacity, facilities, or shifts converted from old work to new; salespeople, engineers, or management attention reassigned; other worthwhile projects deferred, deprioritized, or passed over; or an activity being wound down, exited, or allowed to run off in order to free what the newer effort needs. Management need not be divesting or shrinking anything outright — the point is that the flow of resources has changed direction and management says so. (3) MANAGEMENT TREATS THE REDIRECTION AS DEFINING, AND SAYS THE NUMBERS STILL DESCRIBE THE OLD ALLOCATION. Management conveys, directly or plainly in substance, that this reallocation is intended to make the newer effort a much larger share of the company over time, that what the company becomes depends substantially on it, and that the results just reported still mostly reflect the company as it was allocated before — so today's figures describe the old composition while the money has already moved. Candor about the near-term cost, dilution of current results, strain, or risk of the shift strengthens rather than weakens a YES. The essence is ONE phenomenon: an operating team quietly re-aiming the company's finite internal resources from where the business has been toward where management believes it is going, at a moment when the reported financials still belong to the old allocation. The industry, the resource being moved, and the destination may vary widely — a manufacturer converting lines to a new product generation, a resource company shifting development capital to a different asset type, a retailer or restaurant chain moving store capital into a new format, a services firm reassigning its people to a different kind of work, a healthcare company redirecting development spend to a different modality, or a technology company moving engineering and sales resources onto a different offering all qualify if the substance is there. Answer NO if the company is simply investing in growth across its existing business, or adding a new initiative on top while everything else continues to receive the same resources — additive investment with nothing getting less is not this phenomenon. NO if the destination is only announced, contemplated, under review, at concept stage, or dependent on money the company does not have. NO if the "new" thing is a routine product refresh, ordinary line extension, normal annual innovation, or the company's usual cadence of investment within an unchanged business. NO if the reallocation is forced or defensive — driven by a collapsing legacy business, a lost customer or market, covenant pressure, restructuring, or cost cutting for survival — rather than chosen while the historical business still functions. NO if the resources funding the shift come chiefly from newly raised outside capital rather than from the company's own cash generation, capacity, or people. NO if the shift is described as routine annual budget reprioritization or ordinary portfolio pruning that management does not connect to a different future composition of the company. NO if the newer effort is already the bulk of the business, so there is no mix change still ahead. NO if management describes the redirection but conveys no sense that it will materially change what the company is. NO if the idea appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
NOAH Noah Holdings Limited Q1 2024 2024-05-30 D
HUYA HUYA Inc. Q4 2023 2024-03-19 C
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
SANG Sangoma Technologies Corporation Q2 2024 2024-02-08 D
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
DKS DICK'S Sporting Goods, Inc. Q4 2022 2023-03-07 B
TWLO Twilio Inc. Q4 2022 2023-02-15 D
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
CTHR Charles & Colvard, Ltd. Q1 2023 2022-11-06 F
AWRE Aware, Inc. Q3 2022 2022-10-30 F
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
LOB Live Oak Bancshares, Inc. Q3 2018 2018-10-25 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
HPE Hewlett Packard Enterprise Company Q2 2018 2018-05-22 B+
SCVL Shoe Carnival, Inc. Q4 2017 2018-03-27 C+
FLEX Flex Ltd. Q1 2018 2017-07-28 F
DHX DHI Group, Inc. Q2 2017 2017-07-28 D
BIIB Biogen Inc. Q2 2017 2017-07-25 B
DUK Duke Energy Corporation Q2 2016 2016-08-04 B
INGR Ingredion Incorporated Q1 2016 2016-05-01 B+

How the model reasoned

DUK · Q2 2016 → YESThe question is about whether Duke Energy is redirecting its own capital and operating resources from historical uses to a newer effort, with all three conditions met. YES The transcript shows Duke Energy's management describing a clear portfolio transition: exiting the Latin American generation business (historical international operations) while redirecting resources toward building a domestic energy infrastructure business focused on natural gas infrastructure, renewables, and grid modernization. This is framed as a strategic shift to a lower-carbon future, with a 30 billion dollar capital plan already in motion for these initiatives. Management explicitly ties the redirection to defining the company's future composition, noting that after these transactions, the portfolio will emphasize low-risk domestic infrastructure rather than the prior mix of international and coal-heavy assets.
PRPH · Q1 2023 → YESThe question is about whether management describes a redirection of the company's own capital and operating resources from historical activities to a newer effort. YES The transcript shows management describing a clear redirection: COVID testing (the historical windfall) is winding down naturally as PHE ends, freeing resources, while incremental capital, people, and attention are flowing into newer efforts like manufacturing capacity, Nebula Genomics, esophageal cancer test, and Linebacker. Ted Karkus explicitly states 2024 is a "transition year" focused on building underlying company value rather than earnings, with COVID revenues expected to weaken. They are converting lab infrastructure from COVID to full clinical and genomic testing, hiring for new assets, and investing in R&D and validations—all funded from prior cash generation, not new external capital.
IRT · Q2 2018 → YESThe question is about whether management describes a redirection of the company's own capital and operating resources to something new, away from historical uses, treating this as defining the company...YES The transcript shows management describing a clear redirection of capital: proceeds from selling five non-core communities are being recycled to acquire assets in preferred scalable markets (Atlanta, Orlando, Tampa, Carolinas), with two acquisitions already completed post-quarter. This is framed as accelerating portfolio concentration in markets with stronger fundamentals, while the value-add program on existing properties is positioned as a key driver of incremental NOI and NAV. Current results still reflect the pre-reallocation portfolio, and management explicitly ties the shift to defining future scale and composition.

More from the question bank

Losses shrinking while the business growsReality beat their plan and they're leaning Already inside the gateSomeone else's clock has started running agaPriced for one buyer, wanted by manySecond demand front open and fundedAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.